Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05892718 · ClinicalTrials.gov registry record · Phase 1
A Safety and Efficacy Study of HCB101, Fc-fusion Protein Targeting SIRPα-CD47 Pathway, in Solid or Hematological Tumors
A Phase 1 study of Advanced Solid Tumor and Refractory Non-Hodgkin Lymphoma, sponsored by FBD Biologics Limited.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 80
- Enrollment target
- 8
- Study locations
NCT05892718: Recruiting Phase 1 study of Advanced Solid Tumor and Refractory Non-Hodgkin Lymphoma, sponsored by FBD Biologics Limited.
NCT05892718 is a Phase 1 study of Advanced Solid Tumor and Refractory Non-Hodgkin Lymphoma that is actively recruiting participants, run by FBD Biologics Limited. The registered enrollment target is 80 participants, below the 193-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (59% lower). The trial reports 8 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05892718, a Phase 1 study of Advanced Solid Tumor and Refractory Non-Hodgkin Lymphoma, is actively recruiting participants, sponsored by FBD Biologics Limited.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 80 participants
- Enrollment target
- 8
- Study locations
Study Summary
The purpose of this study is to find out whether IV injection of HCB101 is an effective treatment for different types of advanced solid tumors or relapsed and refractory non-Hodgkin lymphoma and what side effects (unwanted effects) may occur in subjects aged 18 years old and above.
Primary Outcome
To evaluate the safety and tolerability of HCB101
Conditions Studied
Interventions
- DRUG HCB101
Study Locations (8)
Other
- Taipei Medical University - Shuang Ho Hospital, Ministry of Health and Welfare - New Taipei City
- National Taiwan University Hospital - Taipei
- Taipei Veterans General Hospital - Taipei
Florida
- Hematology-Oncology Associates of the Treasure Coast - Port Saint Lucie
North Carolina
- Carolina BioOncology - Huntersville
South Carolina
- Greenville Hospital System University Medical Center (ITOR) - Greenville
Texas
- UT Southwestern Medical Center - Dallas
Zhejiang
- Hangzhou First People's Hospital - Hangzhou
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2023-10-02 |
| Est. Completion | 2029-11-15 |
| Phase | Phase 1 |
What NCT05892718 shows while recruiting
NCT05892718 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 80 participants, a relatively small participant target, below the 193-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (59% lower).
The record links to 2 conditions, with Advanced Solid Tumor appearing as the primary indexed condition, and to 1 intervention - of which HCB101 is the first listed.
NCT05892718 lists 8 locations in 6 states (Other, Florida, North Carolina).
Frequently Asked Questions
What is clinical trial NCT05892718 about?
NCT05892718 is a clinical study titled "A Safety and Efficacy Study of HCB101, Fc-fusion Protein Targeting SIRPα-CD47 Pathway, in Solid or Hematological Tumors". The purpose of this study is to find out whether IV injection of HCB101 is an effective treatment for different types of advanced solid tumors or relapsed and refractory non-Hodgkin lymphoma and what side effects (unwanted effects) may occur in subjects aged 18 years old and above.
What is the current status of trial NCT05892718?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 80 participants. The study started on 2023-10-02. Estimated completion is 2029-11-15.
What conditions does trial NCT05892718 study?
This clinical trial studies the following conditions: Advanced Solid Tumor, Refractory Non-Hodgkin Lymphoma.
What interventions are being tested in trial NCT05892718?
The interventions under investigation include: HCB101 (DRUG).
Who is sponsoring clinical trial NCT05892718?
This trial is sponsored by FBD Biologics Limited, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05892718 being conducted?
This trial has 8 study locations across Florida, North Carolina, South Carolina, Texas, Zhejiang. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Solid Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05892718's enrollment target sits among peer trials
80 134th of 189 higher than 54 of 189 other Advanced Solid Tumor trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Advanced Solid Tumor trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
PM14 Administered Intravenously to Patients with Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study of EP0031 in Patients With Advanced RET-altered Malignancies
RECRUITING · Phase 1
-
Study of AVZO-021 in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
A First-in-Human Study of YL217 in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01243931 · 80 participants · NA
Optical Coherence Tomography Guided Transepithelial Phototherapeutic Keratectomy
- NCT01659203 · 80 participants · Phase 1
Proton or Photon RT for Retroperitoneal Sarcomas
- NCT01803451 · 80 participants · Early Phase 1
Glucagon-like Peptide 1, Glucose Metabolism and Gastric Bypass
- NCT01964859 · 80 participants · Phase 2
Feasibility Study for Fibroblast Autologous Skin Grafts
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI